Programming Tumor-reactive Effector Memory CD8+ T Cells in Vitro Obviates the Requirement for in Vivo Vaccination

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2009 Jun 30

PMID 19561320

Citations 22

Authors

Christopher A Klebanoff

Zhiya Yu

Leroy N Hwang

Douglas C Palmer

Luca Gattinoni

Nicholas P Restifo

Affiliations

Soon will be listed here.

Abstract

Naive and memory CD8(+) T cells can undergo programmed activation and expansion in response to a short T-cell receptor stimulus, but the extent to which in vitro programming can qualitatively substitute for an in vivo antigen stimulation remains unknown. We show that self-/tumor-reactive effector memory CD8(+) T cells (T(EM)) programmed in vitro either with peptide-pulsed antigen-presenting cells or plate-bound anti-CD3/anti-CD28 embark on a highly stereotyped response of in vivo clonal expansion and tumor destruction nearly identical to that of vaccine-stimulated T(EM) cells. This programmed response was associated with an interval of antigen-independent interferon-gamma (IFN-gamma) release that facilitated the dynamic expression of the major histocompatibility complex class I restriction element H-2D(b) on responding tumor cells, leading to recognition and subsequent tumor lysis. Delaying cell transfer for more than 24 hours after stimulation or infusion of cells deficient in IFN-gamma entirely abrogated the benefit of the programmed response, whereas transfer of cells unable to respond to IFN-gamma had no detriment to antitumor immunity. These findings extend the phenomenon of a programmable effector response to memory CD8(+) T cells and have major implications for the design of current adoptive-cell transfer trials.

Citing Articles

Memory CD8 T cell responses to cancer.

Han J, Khatwani N, Searles T, Turk M, Angeles C Semin Immunol. 2020; 49:101435.

PMID: 33272898 PMC: 7738415. DOI: 10.1016/j.smim.2020.101435.

A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy.

Casadesus A, Deligne C, Diallo B, Sosa K, Josseaume N, Mesa C Oncoimmunology. 2020; 9(1):1770565.

PMID: 32923126 PMC: 7458652. DOI: 10.1080/2162402X.2020.1770565.

CD4 T cells support polyfunctionality of cytotoxic CD8 T cells with memory potential in immunological control of tumor.

Imai N, Tawara I, Yamane M, Muraoka D, Shiku H, Ikeda H Cancer Sci. 2020; 111(6):1958-1968.

PMID: 32304127 PMC: 7293103. DOI: 10.1111/cas.14420.

An effective mouse model for adoptive cancer immunotherapy targeting neoantigens.

Hanada K, Yu Z, Chappell G, Park A, Restifo N JCI Insight. 2019; 4(10).

PMID: 31092734 PMC: 6542630. DOI: 10.1172/jci.insight.124405.

A kinetic investigation of interacting, stimulated T cells identifies conditions for rapid functional enhancement, minimal phenotype differentiation, and improved adoptive cell transfer tumor eradication.

Zhou J, Bethune M, Malkova N, Sutherland A, Comin-Anduix B, Su Y PLoS One. 2018; 13(1):e0191634.

PMID: 29360859 PMC: 5779691. DOI: 10.1371/journal.pone.0191634.

References

Gattinoni L, Finkelstein S, Klebanoff C, Antony P, Palmer D, Spiess P . Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005; 202(7):907-12. PMC: 1397916. DOI: 10.1084/jem.20050732. View

Bohm W, Thoma S, Leithauser F, Moller P, Schirmbeck R, Reimann J . T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. J Immunol. 1998; 161(2):897-908. View

Leen A, Rooney C, Foster A . Improving T cell therapy for cancer. Annu Rev Immunol. 2006; 25:243-65. DOI: 10.1146/annurev.immunol.25.022106.141527. View

Johnson L, Morgan R, Dudley M, Cassard L, Yang J, Hughes M . Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009; 114(3):535-46. PMC: 2929689. DOI: 10.1182/blood-2009-03-211714. View

Kennedy-Nasser A, Brenner M . T-cell therapy after hematopoietic stem cell transplantation. Curr Opin Hematol. 2007; 14(6):616-24. DOI: 10.1097/MOH.0b013e3282ef615a. View

Porter D, Levine B, Bunin N, Stadtmauer E, Luger S, Goldstein S . A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood. 2005; 107(4):1325-31. DOI: 10.1182/blood-2005-08-3373. View

Rapoport A, Stadtmauer E, Aqui N, Badros A, Cotte J, Chrisley L . Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med. 2005; 11(11):1230-7. DOI: 10.1038/nm1310. View

Overwijk W, Theoret M, Finkelstein S, Surman D, de Jong L, Vyth-Dreese F . Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003; 198(4):569-80. PMC: 2194177. DOI: 10.1084/jem.20030590. View

Dalton D, Keshav S, Figari I, Bradley A, Stewart T . Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science. 1993; 259(5102):1739-42. DOI: 10.1126/science.8456300. View

10.

Klebanoff C, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones A, Finkelstein S . Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A. 2005; 102(27):9571-6. PMC: 1172264. DOI: 10.1073/pnas.0503726102. View

11.

Gattinoni L, Klebanoff C, Palmer D, Wrzesinski C, Kerstann K, Yu Z . Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005; 115(6):1616-26. PMC: 1137001. DOI: 10.1172/JCI24480. View

12.

Lollini P, Colombo M, De Giovanni C, Nicoletti G, Parmiani G, Prodi G . In vivo reexpression of H-2 antigens in B16 melanoma cells. Exp Clin Immunogenet. 1985; 2(1):14-23. View

13.

Belz G, Bedoui S, Kupresanin F, Carbone F, Heath W . Minimal activation of memory CD8+ T cell by tissue-derived dendritic cells favors the stimulation of naive CD8+ T cells. Nat Immunol. 2007; 8(10):1060-6. DOI: 10.1038/ni1505. View

14.

Dudley M, Wunderlich J, Robbins P, Yang J, Hwu P, Schwartzentruber D . Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298(5594):850-4. PMC: 1764179. DOI: 10.1126/science.1076514. View

15.

Dudley M, Wunderlich J, Yang J, Sherry R, Topalian S, Restifo N . Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005; 23(10):2346-57. PMC: 1475951. DOI: 10.1200/JCO.2005.00.240. View

16.

Rapoport A, Levine B, Badros A, Meisenberg B, Ruehle K, Nandi A . Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells. Bone Marrow Transplant. 2003; 33(1):53-60. DOI: 10.1038/sj.bmt.1704317. View

17.

Pule M, Savoldo B, Myers G, Rossig C, Russell H, Dotti G . Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008; 14(11):1264-70. PMC: 2749734. DOI: 10.1038/nm.1882. View

18.

Overwijk W, Surman D, Tsung K, Restifo N . Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. Methods. 1997; 12(2):117-23. DOI: 10.1006/meth.1997.0461. View

19.

Sikora A, Jaffarzad N, Hailemichael Y, Gelbard A, Stonier S, Schluns K . IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol. 2009; 182(12):7398-407. PMC: 2774140. DOI: 10.4049/jimmunol.0802982. View

20.

Gattinoni L, Zhong X, Palmer D, Ji Y, Hinrichs C, Yu Z . Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med. 2009; 15(7):808-13. PMC: 2707501. DOI: 10.1038/nm.1982. View